Geeta A. Maggu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Imeglimin is a novel agent currently in development to treat type 2 diabetes. Laboratory studies have demonstrated that it has the potential to impact the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis, and increased beta-cell apoptosis. Preliminary human studies that have(More)
  • 1